Analyst Thomas Smith from Leerink Partners reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) and keeping the price target at $50.00.
Thomas Smith has given his Buy rating due to a combination of factors related to Viridian Therapeutics’ promising pipeline and strategic progress. The company has reported that all clinical and regulatory timelines are on track, which is a positive indicator for future developments. The anticipated BLA submission for veligrotug in the second half of 2025, based on successful Phase 3 trial results, suggests potential approval and market entry by the second half of 2026. Additionally, the company plans to submit an MAA to the European Medicines Agency in the first half of 2026, marking a significant step in their European market strategy.
Furthermore, the ongoing development of their FcRn inhibitors, with promising early results and upcoming clinical milestones, adds to the company’s growth prospects. The competitive profile of veligrotug in the thyroid eye disease market and the potential of SC VRDN-003 as a leading subcutaneous treatment option further support the Buy rating. Overall, these factors collectively enhance the confidence in Viridian Therapeutics’ future performance and market potential.
In another report released on February 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.
VRDN’s price has also changed slightly for the past six months – from $14.975 to $15.290, which is a 2.10% increase.